BB Biotech AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BION.SW research report →
Price Chart
About the company
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach.
- CEO
- Daniel Koller
- IPO
- 1993
- Employees
- 10
- HQ
- Kusnacht, CH
Get TickerSpark's AI analysis on BION.SW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.04B
- P/E
- 2.25
- Fwd P/E
- 21.36
- PEG
- 0.00
- P/S
- 20.81
- P/B
- 0.99
- EV/EBITDA
- 2.10
- Div Yield
- 4.08%
- Gross Margin
- 100.00%
- Op Margin
- 924.92%
- Net Margin
- 924.03%
- ROE
- 49.95%
- ROIC
- 43.70%
Latest fiscal year · YoY change
- Revenue
- $76.81M-31.2%
- Gross Profit
- $76.76M-31.2%
- Op Income
- $586.83M
- Net Income
- $578.13M+661.7%
- EPS
- $10.54+663.8%
- OCF Growth
- +1.5%
- FCF Growth
- +1.5%
- 52W High
- $55.90
- 52W Low
- $31.90
- 50D MA
- $49.78
- 200D MA
- $46.38
- Beta
- 0.93
- RSI (14)
- 70
- Avg Volume
- 82.60K
No earnings-call transcripts are available for BION.SW yet.
- Free Float
- 99.5%
- Shares Outstanding
- 55.15M
- Float Shares
- 54.86M
Our BION.SW coverage
Recent articles, reports, and earnings notes.
No research on BION.SW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BION.SW report →